– CANADA, Victoria – ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA), a leader in AI-driven biotherapeutic research and technology, today announced the appointment of Mitch Levine as Chairman of the Board of Directors, bringing a wealth of experience from the life sciences industry and financial strategy, particularly in Nasdaq market operations.
About Mitch Levine
As CEO and Chairman of SmartHealth Dx since 2022, Mitch Levine has focused on the company’s strategy, and operational efficiency, and boosted corporate value. At Oncocyte, he drove significant growth as CFO from 2017 to 2022, overseeing all financial operations of the company, managing capital raises, navigating Nasdaq complexities, and leading major acquisitions and a key licensing deal in China. His capital markets expertise was widely recognized as the Founder and Managing Member of Enable Capital Management, LLC, where for 17 years they provided growth capital to small- and mid-sized public companies, many traded on Nasdaq. His background also includes a foundational role at The Shemano Group, a San Francisco-based investment bank focused on technology and life sciences sectors.
About ImmunoPrecise Antibodies Ltd
ImmunoPrecise Antibodies Ltd. has several subsidiaries in North America and Europe including entities such as Talem Therapeutics LLC, BioStrand BV, ImmunoPrecise Antibodies (Canada) Ltd., and ImmunoPrecise Antibodies (Europe) B.V. The IPA Family is a biotherapeutic research and technology group that leverages systems biology, multi-omics modeling, and complex artificial intelligence systems to support its proprietary technologies in platform-based antibody discovery. Services include highly specialized, full-continuum therapeutic biologics discovery, development, and out-licensing to support its business partners in their quest to discover and develop novel biologics against the most challenging targets.
For more, visit www.ipatherapeutics.com.
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
